Compare Stocks: LEXX, ADXS, UPC, and VIRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
LEXX Lexaria Bioscience	$11.52 +11.6%	$8.09	$4.21 ▼ $23.25	$19.04M	0.38	12,562 shs	32,244 shs
UPC Universe Pharmaceuticals	$5.23 -9.5%	$4.71	$2.00 ▼ $17.96	$26.28M	1.52	844,335 shs	29,059 shs
VIRI Virios Therapeutics	$2.06 -4.2%	$1.57	$0.13 ▼ $1.04	$39.67M	1.58	1.05 million shs	45,489 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,026.03%
LEXX Lexaria Bioscience	+14.16%	+87.98%	+8.16%	+19.18%	-16.05%
UPC Universe Pharmaceuticals	+2.30%	-18.48%	+29.89%	+127.56%	+64.20%
VIRI Virios Therapeutics	0.00%	+19.11%	+55.80%	+26.47%	-56.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
LEXX Lexaria Bioscience	$11.52 +11.6%	$8.09	$4.21 ▼ $23.25	$19.04M	0.38	12,562 shs	32,244 shs
UPC Universe Pharmaceuticals	$5.23 -9.5%	$4.71	$2.00 ▼ $17.96	$26.28M	1.52	844,335 shs	29,059 shs
VIRI Virios Therapeutics	$2.06 -4.2%	$1.57	$0.13 ▼ $1.04	$39.67M	1.58	1.05 million shs	45,489 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,026.03%
LEXX Lexaria Bioscience	+14.16%	+87.98%	+8.16%	+19.18%	-16.05%
UPC Universe Pharmaceuticals	+2.30%	-18.48%	+29.89%	+127.56%	+64.20%
VIRI Virios Therapeutics	0.00%	+19.11%	+55.80%	+26.47%	-56.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
LEXX Lexaria Bioscience	2.00	Hold	$22.50	95.31% Upside
UPC Universe Pharmaceuticals	1.00	Sell	N/A	N/A
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LEXX, ADXS, UPC, and VIRI Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	11.05	N/A	N/A	($2.06) per share	-0.29
LEXX Lexaria Bioscience	$194K	98.16	N/A	N/A	$2.00 per share	5.76
UPC Universe Pharmaceuticals	$17.74M	1.48	N/A	N/A	$99.64 per share	0.05
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$5.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	-$11.90M	-$5.10	N/A	N/A	N/A	N/A	-174.93%	-143.89%	10/28/2026 (Estimated)
UPC Universe Pharmaceuticals	-$3.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest LEXX, ADXS, UPC, and VIRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/29/2026	Q2 2026	UPC Universe Pharmaceuticals	N/A	-$1.38	N/A	-$1.38	N/A	$4.52 million
7/13/2026	Q3 2026	LEXX Lexaria Bioscience	-$0.06	-$0.08	-$0.02	-$1.20	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	10.61	10.61
UPC Universe Pharmaceuticals	0.04	4.05	3.90
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
LEXX Lexaria Bioscience	13.06%
UPC Universe Pharmaceuticals	0.18%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
LEXX Lexaria Bioscience	8.39%
UPC Universe Pharmaceuticals	57.38%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	59.31 million	42.36 million	Not Optionable
LEXX Lexaria Bioscience	7	1.65 million	1.51 million	Not Optionable
UPC Universe Pharmaceuticals	220	5.02 million	2.14 million	N/A
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data

LEXX, ADXS, UPC, and VIRI Headlines

Recent News About These Companies

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LEXX, ADXS, UPC, and VIRI Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)

As of 08/17/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Lexaria Bioscience NASDAQ:LEXX

$11.52 +1.20 (+11.63%)

Closing price 04:00 PM Eastern

Extended Trading

$10.79 -0.73 (-6.33%)

As of 04:36 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Universe Pharmaceuticals NASDAQ:UPC

$5.23 -0.55 (-9.52%)

Closing price 04:00 PM Eastern

Extended Trading

$5.28 +0.04 (+0.86%)

As of 04:27 PM Eastern

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Virios Therapeutics NASDAQ:VIRI

$2.06 -0.09 (-4.19%)

As of 08/17/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEXX, ADXS, UPC, and VIRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEXX, ADXS, UPC, and VIRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEXX, ADXS, UPC, and VIRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LEXX, ADXS, UPC, and VIRI Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

Lexaria Bioscience NASDAQ:LEXX

Universe Pharmaceuticals NASDAQ:UPC

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEXX, ADXS, UPC, and VIRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEXX, ADXS, UPC, and VIRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEXX, ADXS, UPC, and VIRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LEXX, ADXS, UPC, and VIRI Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

Lexaria Bioscience NASDAQ:LEXX

Universe Pharmaceuticals NASDAQ:UPC

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools